Harpers:

From the jury selection process that took place over three days in June for the trial of Martin Shkreli, an investor and hedge fund founder who is facing eight counts of securities and wire fraud. In 2015, when Shkreli was CEO of Turing Pharmaceuticals, the company raised the price of its drug Daraprim by 5,000 percent. In 2016, Shkreli was widely criticized for defending the 400 percent increase in the price of EpiPen, an emergency allergy injection sold by Mylan. More than two hundred potential jurors were excused from the trial. Judge Kiyo Matsumoto presided. Benjamin Brafman is a lawyer representing Shkreli.

I guarantee this will be the funniest thing you read about Martin Shkreli all year. Thanks to my friend John Welch for the link.